Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First Interchangeability Designation Opens Doors For Biosimilars

Pharmacy Substitution For Semglee Now Possible Without Prescriber Intervention

Executive Summary

An FDA decision to award Viatris a landmark interchangeability designation for its Semglee insulin glargine biosimilar has been welcomed by industry representatives.

You may also be interested in...



Managing Lifecycles Amid Stifling Competition

Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.

Amgen Biosimilars Study Predicts Significant Advances

Amgen’s 2021 Biosimilars Trends Report predicts several imminent advancements in the biosimilars space, especially with the expected US launches of biosimilars to Humira in 2023. According to Amgen, the marketplace is poised to see further growth.

Viatris Dishes On Insulin Aspart Biosimilar As Key Date Passes

Viatris has provided an update on its biosimilar pipeline, covering assets including insulin glargine, insulin aspart, aflibercept and bevacizumab, as part of its second quarter strategic update.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel